Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Storz

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Biotechnology|November 21, 2017
CRISPR Cas9 - Licensing the unlicensableUlrich Storz
Journal of Biotechnology|February 20, 2026
The complex patent situation regarding antibody Fc engineeringUlrich Storz
Human Antibodies|September 17, 2019
The nine lives of epitope-based antibody patentsUlrich Storz
Journal of Biotechnology|November 20, 2023
The CRISPR Cas patent files, part 1: Cas9 - Where to we stand at the 10 year halftime?Ulrich Storz
Expert Opinion on Therapeutic Patents|June 18, 2021
The patent maze of COVID 19 vaccinesUlrich Storz
Human Antibodies|February 15, 2018
Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and SimponiUlrich Storz
Journal of Biotechnology|August 25, 2025
The CRISPR Cas patent files, part 4: All back to zero, think again!Ulrich Storz
Journal of Biotechnology|January 5, 2024
The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9?Ulrich Storz
Recent Patents on Biotechnology|June 17, 2022
WITHDRAWN: Moderna’s COVID 19 Patent Under the Magnifying GlassUlrich Storz
Mabs|March 29, 2012
The Cabilly patents: status quo and relevance for antibody companiesUlrich Storz
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Biotechnology|November 21, 2017
CRISPR Cas9 - Licensing the unlicensableUlrich Storz
Journal of Biotechnology|February 20, 2026
The complex patent situation regarding antibody Fc engineeringUlrich Storz
Human Antibodies|September 17, 2019
The nine lives of epitope-based antibody patentsUlrich Storz
Journal of Biotechnology|November 20, 2023
The CRISPR Cas patent files, part 1: Cas9 - Where to we stand at the 10 year halftime?Ulrich Storz
Expert Opinion on Therapeutic Patents|June 18, 2021
The patent maze of COVID 19 vaccinesUlrich Storz
Human Antibodies|February 15, 2018
Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and SimponiUlrich Storz
Journal of Biotechnology|August 25, 2025
The CRISPR Cas patent files, part 4: All back to zero, think again!Ulrich Storz
Journal of Biotechnology|January 5, 2024
The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9?Ulrich Storz
Recent Patents on Biotechnology|June 17, 2022
WITHDRAWN: Moderna’s COVID 19 Patent Under the Magnifying GlassUlrich Storz
Mabs|March 29, 2012
The Cabilly patents: status quo and relevance for antibody companiesUlrich Storz
Pageof 3